Marie-Claire Peakman
Director/Board Member at Mozart Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Peter Joyce | M | - |
Grey Wolf Therapeutics Ltd.
 Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | - |
| Katie Fanning | F | - |
Mozart Therapeutics, Inc.
 Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| Rana Al-Hallaq | M | - |
Pfizer Venture Investments LLC
 Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 6 years |
| Christopher O’Donnell | M | 55 |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 6 years |
| Thomas Mccarthy | M | - |
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | - |
| Lucio Iannone | M | 41 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 3 years |
| Sally Dewhurst | F | - |
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | 1 years |
| Jasmina Marjanovic | F | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 1 years |
| Jan Beck | M | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 2 years |
| Julie Gilmore | M | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| Emma Johnson | F | 28 |
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | 1 years |
| Kirsty McCarthy | F | - |
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | - |
| Steven Gillis | M | 71 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| Denis Patrick | M | - |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 6 years |
| Barbara Dalton | M | 69 |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 17 years |
| Peter Dudek | M | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 4 years |
| Michael Baran | M | - |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 6 years |
| K. Christopher Garcia | M | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| Henrijette Richter | M | 53 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| Thierry Hercend | M | - |
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | - |
| Irena Melnikova | M | - |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 2 years |
| Raphaël Wisniewski | M | 54 |
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | - |
| Thomas Daniel | M | 70 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 4 years |
| Brent Ahrens | M | 61 |
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | - |
| Rabab Nasrallah | F | - |
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Fiona MacLaughlin | M | - |
The University of Nottingham
| 7 years |
| Stuart Bradley | M | - |
The University of Nottingham
| 5 years |
| Parmjit Singh Dhanda | M | 52 |
The University of Nottingham
| 6 years |
| Geoff Neil | M | - |
The University of Nottingham
| 7 years |
| George Zornas | M | 56 |
The University of Nottingham
| 5 years |
| Yiu Ming Tang | M | 69 |
The University of Nottingham
| 7 years |
| Adam Key | M | - |
The University of Nottingham
| 4 years |
| Yong Chua Teo | M | - |
The University of Nottingham
| 3 years |
| Kweku Adoboli | M | 42 |
The University of Nottingham
| 14 years |
| Neil Fairfield | M | 49 |
The University of Nottingham
| 3 years |
| Kah Sung Chow | M | 58 |
The University of Nottingham
| 2 years |
| Robert Hamlin | M | - |
The University of Nottingham
| 3 years |
| Shing Joe Ng | M | 57 |
The University of Nottingham
| 4 years |
| Richard Toon | M | 53 |
The University of Nottingham
| 4 years |
| Catherine Davidson | F | - |
The University of Nottingham
| 4 years |
| Oei Wee Guan | M | 55 |
The University of Nottingham
| 3 years |
| Huey Miin Wong | F | 48 |
The University of Nottingham
| 4 years |
| Yee Wah Chan | M | 58 |
The University of Nottingham
| 2 years |
| Wai Han Hui | F | 56 |
The University of Nottingham
| 2 years |
| Charlie Thomas | M | - |
The University of Nottingham
| 4 years |
| Tom Jack | M | - |
The University of Nottingham
| 3 years |
| Stephen Hartman | M | 54 |
The University of Nottingham
| 3 years |
| Laurent Deckers | M | - |
The University of Nottingham
| 1 years |
| Stephen Nuttall | M | - |
The University of Nottingham
| 3 years |
| Steve Howard | M | - |
The University of Nottingham
| 5 years |
| Mike Barker | M | - |
The University of Nottingham
| 3 years |
| Michael Denis Barker | M | 48 |
The University of Nottingham
| 4 years |
| Soong Meng Tham | M | 59 |
The University of Nottingham
| 4 years |
| Nikola Trbovic | M | - |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 7 years |
| Mei Wan Yap | F | 57 |
The University of Nottingham
| 3 years |
| Andrew David Deakin | M | 51 |
The University of Nottingham
| 3 years |
| Stephen Lamb | M | 51 |
The University of Nottingham
| 3 years |
| Abel N J. Haque | M | - |
The University of Nottingham
| 3 years |
| Rewadee Jantamaneechote | M | 49 |
The University of Nottingham
| 3 years |
| Gareth Hywel Jones | M | 56 |
The University of Nottingham
| 4 years |
| Nadzri Bin Yahaya | M | 67 |
The University of Nottingham
| 1 years |
| Kin Fun Kwok | M | 73 |
The University of Nottingham
| 3 years |
| Ahmet Bal | M | 67 |
The University of Nottingham
| 2 years |
| Muhammad Azmil Abdul Shukor | M | - |
The University of Nottingham
| 4 years |
| Simon Piercy | M | - |
The University of Nottingham
| 4 years |
| Dean Dorrell | M | - |
The University of Nottingham
| 4 years |
| Andy Davidson | M | - |
The University of Nottingham
| 3 years |
| Kam Man Yip | F | 57 |
The University of Nottingham
| 4 years |
| Osama Mohammed Al-Orayidh | M | 60 |
The University of Nottingham
| 1 years |
| Paul David Matthews | M | 56 |
The University of Nottingham
| 4 years |
| Caroline Gulliver | F | 59 |
The University of Nottingham
| 4 years |
| Chun Wai Kwong | M | 59 |
The University of Nottingham
| 4 years |
| Peter George Lutz | M | 63 |
The University of Nottingham
| 2 years |
| Bill Burkoth | M | 47 |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 17 years |
| Jason Rogers | M | - |
The University of Nottingham
| 4 years |
| Todd Chalem | M | - |
The University of Nottingham
| 4 years |
| Louis Joseph Nisbet | M | - |
The University of Nottingham
| - |
| Matthew Leslie Sutcliffe | M | - |
The University of Nottingham
| 3 years |
| Peter McMichael | M | - |
The University of Nottingham
| 4 years |
| Robert Schofield | M | 53 |
The University of Nottingham
| 3 years |
| Graham John Heddle | M | 56 |
The University of Nottingham
| 4 years |
| Mark Lunn | M | - |
The University of Nottingham
| 4 years |
| Thomas Cormack | M | - |
The University of Nottingham
| 3 years |
| Maurice Benisty | M | 52 |
The University of Nottingham
| 3 years |
| Ying Jiao | M | 61 |
The University of Nottingham
| 1 years |
| Neville F. Rieger | M | - |
The University of Nottingham
| 4 years |
| Andy Bell | M | 58 |
The University of Nottingham
| 4 years |
| John Savill | M | - |
The University of Nottingham
| 1 years |
| Nicos Michaelas | M | 51 |
The University of Nottingham
| 4 years |
| Edward Aston Wass | M | 53 |
The University of Nottingham
| 3 years |
| Ian M. Oades | M | 56 |
The University of Nottingham
| 4 years |
| Martin J. Hughes | M | - |
The University of Nottingham
| 3 years |
| Kamal bin Khalid | M | 53 |
The University of Nottingham
| 3 years |
| Iwan Azlan bin Mokhtar | M | 57 |
The University of Nottingham
| 3 years |
| Jonathan Terrett | M | - |
The University of Nottingham
| 3 years |
| Hikmahanto Juwana | M | 58 |
The University of Nottingham
| 3 years |
| Chris Williams | M | - |
The University of Nottingham
| 4 years |
| Robert Scargill | M | - |
The University of Nottingham
| 4 years |
| Neil Pegg | M | - |
The University of Nottingham
| 3 years |
| Matt Harrison | M | - |
The University of Nottingham
| 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 82 | 82.00% |
| United States | 18 | 18.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Marie-Claire Peakman
- Personal Network
